Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
2005 1
2008 2
2009 2
2011 1
2012 2
2013 2
2014 7
2015 5
2016 7
2017 18
2018 23
2019 26
2020 21
2021 20
2022 24
2023 17
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. Among authors: hendifar a. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.
TOPAZ-1: a new standard of care for advanced biliary tract cancers?
Ebia MI, Sankar K, Osipov A, Hendifar AE, Gong J. Ebia MI, et al. Among authors: hendifar ae. Immunotherapy. 2023 May;15(7):473-476. doi: 10.2217/imt-2022-0269. Epub 2023 Mar 23. Immunotherapy. 2023. PMID: 36950948 No abstract available.
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB 3rd. Kunz PL, et al. Among authors: hendifar ae. J Clin Oncol. 2023 Mar 1;41(7):1359-1369. doi: 10.1200/JCO.22.01013. Epub 2022 Oct 19. J Clin Oncol. 2023. PMID: 36260828 Free PMC article. Clinical Trial.
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. Strosberg JR, et al. Among authors: hendifar a. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. Lancet Oncol. 2021. PMID: 34793718 Clinical Trial.
Claudin-18.
Wong MT, Singhi AD, Larson BK, Huynh CAT, Balzer BL, Burch M, Dhall D, Gangi A, Gong J, Guindi M, Hendifar AE, Kim SA, de Peralta-Venturina M, Waters KM. Wong MT, et al. Among authors: hendifar ae. Arch Pathol Lab Med. 2022 May 1;147(5):559-567. doi: 10.5858/arpa.2021-0428-OA. Arch Pathol Lab Med. 2022. PMID: 35976638 Free article.
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA, Azar I, Xiu J, Hall MJ, Hendifar AE, Lou E, Hwang JJ, Gong J, Feldman R, Ellis M, Stafford P, Spetzler D, Khushman MM, Sohal D, Lockhart AC, Weinberg BA, El-Deiry WS, Marshall J, Shields AF, Korn WM. Philip PA, et al. Among authors: hendifar ae. Clin Cancer Res. 2022 Jun 13;28(12):2704-2714. doi: 10.1158/1078-0432.CCR-21-3581. Clin Cancer Res. 2022. PMID: 35302596 Free PMC article.
Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels.
Kurth I, Yamaguchi N, Andreu-Agullo C, Tian HS, Sridhar S, Takeda S, Gonsalves FC, Loo JM, Barlas A, Manova-Todorova K, Busby R, Bendell JC, Strauss J, Fakih M, McRee AJ, Hendifar AE, Rosen LS, Cercek A, Wasserman R, Szarek M, Spector SL, Raza S, Tavazoie MF, Tavazoie SF. Kurth I, et al. Among authors: hendifar ae. Sci Adv. 2021 Oct 8;7(41):eabi7511. doi: 10.1126/sciadv.abi7511. Epub 2021 Oct 6. Sci Adv. 2021. PMID: 34613776 Free PMC article.
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.
Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, Mikhail S, Chung V, Sahai V, Sohal DPS, Bellakbira S, Thach D, Rahib L, Madhavan S, Matrisian LM, Petricoin EF 3rd. Pishvaian MJ, et al. Among authors: hendifar a. Lancet Oncol. 2020 Apr;21(4):508-518. doi: 10.1016/S1470-2045(20)30074-7. Epub 2020 Mar 2. Lancet Oncol. 2020. PMID: 32135080 Free PMC article.
Symptom Management in Pancreatic Cancer.
Lee KG, Roy V, Laszlo M, Atkins KM, Lin KJ, Tomassian S, Hendifar AE. Lee KG, et al. Among authors: hendifar ae. Curr Treat Options Oncol. 2021 Jan 2;22(1):8. doi: 10.1007/s11864-020-00801-4. Curr Treat Options Oncol. 2021. PMID: 33387071 Review.
Pancreas Cancer-Associated Weight Loss.
Hendifar AE, Petzel MQB, Zimmers TA, Denlinger CS, Matrisian LM, Picozzi VJ, Rahib L; Precision Promise Consortium. Hendifar AE, et al. Oncologist. 2019 May;24(5):691-701. doi: 10.1634/theoncologist.2018-0266. Epub 2018 Dec 27. Oncologist. 2019. PMID: 30591550 Free PMC article. Review.
167 results